Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00167934 · ClinicalTrials.gov registry record · NA

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

A NA study of Schizophrenia, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
164
Enrollment target
1
Study location

NCT00167934 is a NA study of Schizophrenia that has completed, run by Washington University School of Medicine. The registered enrollment target is 164 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00167934, a NA study of Schizophrenia, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
164 participants
Enrollment target
1
Study location

Study Summary

This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Valproate

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2004-12
Est. Completion 2008-12
Phase NA

What the Registry Record Tells You About NCT00167934

The ClinicalTrials.gov registry entry for NCT00167934 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (25% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00167934 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT00167934 about?

NCT00167934 is a clinical study titled "Determining Metabolic Effects of Valproate and Antipsychotic Therapy". This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate.

What is the current status of trial NCT00167934?

This trial is currently completed. It is a NA study. The enrollment target is 164 participants. The study started on 2004-12. Estimated completion is 2008-12.

What conditions does trial NCT00167934 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00167934?

The interventions under investigation include: Placebo (DRUG), Valproate (DRUG).

Who is sponsoring clinical trial NCT00167934?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00167934 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.